Study identifier:D8170C00001
ClinicalTrials.gov identifier:NCT03362593
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, including Assessment of the Impact of Changes to the Oral Formulation and Determination of Intravenous Pharmacokinetics
Healthy Volunteers
Phase 1
Yes
MEDI7219, Placebo, Formulation without Active Drug
All
186
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 May 2021 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI7219 Experimental Drug | Drug: MEDI7219 Experimental Drug |
Placebo Comparator: Placebo Placebo | Drug: Placebo Placebo |
Placebo Comparator: Formulation without Active Drug Formulation without Active Drug | Drug: Formulation without Active Drug Formulation without Active Drug |